Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$55.16 +3.0%	$43.53	$21.02 ▼ $58.40	$4.39B	-0.16	1.47 million shs	1.05 million shs
KRYS Krystal Biotech	$135.76 -3.3%	$147.00	$122.80 ▼ $219.34	$3.92B	0.65	304,949 shs	129,911 shs
NAGE Niagen Bioscience	$13.68 -3.3%	$9.11	$2.31 ▼ $14.49	$1.08B	2.08	856,021 shs	614,836 shs
RYTM Rhythm Pharmaceuticals	$62.83 -0.3%	$61.97	$39.46 ▼ $69.89	$4.00B	2.3	628,419 shs	323,399 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	+1.13%	-0.70%	+33.87%	+21.31%	+120.50%
KRYS Krystal Biotech	+0.51%	+5.81%	+4.31%	-21.77%	-22.88%
NAGE Niagen Bioscience	+0.50%	+22.85%	+45.32%	+80.36%	+341.88%
RYTM Rhythm Pharmaceuticals	-2.81%	-4.77%	+10.97%	+23.64%	+49.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.7432 of 5 stars	3.5	1.0	4.7	2.5	1.7	0.0
KRYS Krystal Biotech	4.6575 of 5 stars	3.5	1.0	4.7	3.6	3.3	1.9
NAGE Niagen Bioscience	1.4919 of 5 stars	3.5	0.0	0.0	2.6	0.0	0.0
RYTM Rhythm Pharmaceuticals	4.1872 of 5 stars	3.5	3.0	4.3	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	54.90% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	52.52% Upside
NAGE Niagen Bioscience	3.00	Buy	$19.50	41.10% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$76.62	22.62% Upside

Current Analyst Ratings Breakdown

Latest NAGE, AKRO, RYTM, and KRYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00
5/7/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00 ➝ $219.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/6/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00 ➝ $240.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$9.61 per share	N/A
KRYS Krystal Biotech	$333.45M	12.00	$3.52 per share	39.38	$32.85 per share	4.21
NAGE Niagen Bioscience	$107.93M	10.09	N/A	N/A	N/A	∞
RYTM Rhythm Pharmaceuticals	$136.86M	29.04	N/A	N/A	$2.87 per share	21.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$151.76M	-$1.95	N/A	N/A	N/A	N/A	-32.46%	-29.83%	8/8/2025 (Estimated)
KRYS Krystal Biotech	$10.93M	$4.16	46.42	13.73	N/A	30.69%	11.41%	10.40%	8/4/2025 (Estimated)
NAGE Niagen Bioscience	N/A	$0.17	81.29	∞	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	-$184.68M	-$2.81	N/A	N/A	N/A	-230.07%	-367.36%	-77.47%	8/5/2025 (Estimated)

Latest NAGE, AKRO, RYTM, and KRYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.05	17.25	17.25
KRYS Krystal Biotech	N/A	7.28	7.76
NAGE Niagen Bioscience	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	3.49	3.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
KRYS Krystal Biotech	86.29%
NAGE Niagen Bioscience	15.41%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
KRYS Krystal Biotech	13.70%
NAGE Niagen Bioscience	9.39%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	64.26 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	N/A	N/A
RYTM Rhythm Pharmaceuticals	140	63.62 million	58.02 million	Optionable

NAGE, AKRO, RYTM, and KRYS Headlines

Recent News About These Companies

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 2,069 Shares of Stock

June 12 at 5:38 PM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Rating of "Buy" by Analysts

June 12 at 3:57 AM | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of "Buy" from Analysts

June 12 at 3:56 AM | marketbeat.com

Harbor Capital Advisors Inc. Buys 47,045 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 11 at 5:26 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Wedge Capital Management L L P NC

June 11 at 4:36 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells $478,459.55 in Stock

June 10 at 5:47 PM | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year High - Should You Buy?

June 9, 2025 | marketbeat.com

The Rhythm Foundation seeks contract extension to continue programming at Miami Beach Bandshell

June 7, 2025 | msn.com

Heartbeats That Matter: The Silent Risks of Heart Rhythm Disorders

June 7, 2025 | deccanchronicle.com

Millennium Management LLC Sells 21,718 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 7, 2025 | marketbeat.com

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

June 5, 2025 | msn.com

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

June 5, 2025 | benzinga.com

Hennion & Walsh Asset Management Inc. Has $4.75 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 4, 2025 | marketbeat.com

76,084 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Universal Beteiligungs und Servicegesellschaft mbH

June 2, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Holdings Cut by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

May 31, 2025 | marketbeat.com

Stifel Nicolaus Raises Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $94.00

May 30, 2025 | marketbeat.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 4.7% - Here's Why

May 30, 2025 | marketbeat.com

Rhythm Pharmaceuticals (RYTM) Gets Price Target Upgrade by Stifel Amid Obesity Drug Optimism

May 30, 2025 | msn.com

3RYTM : 12 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know

May 29, 2025 | benzinga.com

Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 4.1% - Should You Sell?

May 29, 2025 | marketbeat.com

Funds Go All In On Weight-Loss Leader; Stock Nears Highs

May 29, 2025 | investors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Palantir Scores First $1 Billion Contract; Is It Priced In?
By Chris Markoch | May 27, 2025
View Palantir Scores First $1 Billion Contract; Is It Priced In?
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
By Leo Miller | May 22, 2025
View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
By Leo Miller | May 22, 2025
View These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
Lowe’s Stock Uptrend Can Continue for These 2 Reasons
By Thomas Hughes | May 21, 2025
View Lowe’s Stock Uptrend Can Continue for These 2 Reasons

NAGE, AKRO, RYTM, and KRYS Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$55.16 +1.60 (+2.98%)

As of 02:51 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$135.76 -4.57 (-3.26%)

As of 02:51 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Niagen Bioscience NASDAQ:NAGE

$13.68 -0.46 (-3.25%)

As of 02:33 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Rhythm Pharmaceuticals NASDAQ:RYTM

$62.82 -0.20 (-0.31%)

As of 02:50 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time